Literature DB >> 36278995

Minimally invasive management of concomitant gallstones and common bile duct stones: an updated network meta-analysis of randomized controlled trials.

Jisheng Zhu1, Guiyan Wang2, Bin Xie1, Zhengying Jiang3, Weidong Xiao1, Yong Li4.   

Abstract

BACKGROUND: To update a 2018 meta-analysis on the comparative efficacy and safety of four surgical techniques in patients with concomitant gallstones and common bile duct (CBD) stones.
METHODS: Randomized controlled trials (RCTs) comparing laparoscopic cholecystectomy (LC) plus laparoscopic common bile duct exploration (LCBDE), LC plus preoperative endoscopic retrograde cholangiopancreatography (PreERCP), LC plus intraoperative ERCP (IntraERCP), and LC plus postoperative ERCP (PostERCP) were included. Primary and secondary outcomes were compared using odds ratio, weighted mean difference, and 95% confidence intervals.
RESULTS: Twenty-five RCTs involved 3145 patients were included. Of these, 1188 (37.8%) underwent LC + PreERCP, 1183 (37.6%) LC + LCBDE, 689 (21.9%) LC + IntraERCP, and 85 (2.7%) LC + PostERCP. This analysis demonstrated that LC plus IntraERCP was the most likely approach to achieve technical success and reduce morbidity. No significant differences were observed between the four treatments concerning major morbidity, mortality, and operative time. LC plus LCBDE was effective for increasing biliary leak and conversion as well as decreasing postoperative hemorrhage and total costs. Additionally, LC plus PreERCP was associated with higher postoperative pancreatitis, while LC plus IntraERCP was associated with a shorter length of hospital stay. There was significant heterogeneity in operative time, hospital stay, and total costs (τ2 > 1).
CONCLUSIONS: This analysis provides evidence that LC plus IntraERCP appears to be the optimal strategy for patients with concomitant gallstones and CBD stones owing to its advantage in technical success and morbidity. LC plus LCBDE is associated with higher biliary leak and lower postoperative hemorrhage, whereas LC plus PreERCP is associated with higher postoperative pancreatitis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Common bile duct stones; Endoscopic; Laparoscopic; Network meta-analysis

Year:  2022        PMID: 36278995     DOI: 10.1007/s00464-022-09723-8

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  48 in total

1.  EAES ductal stone study. Preliminary findings of multi-center prospective randomized trial comparing two-stage vs single-stage management.

Authors:  A Cuschieri; E Croce; A Faggioni; J Jakimowicz; A Lacy; E Lezoche; M Morino; V M Ribeiro; J Toouli; J Visa; W Wayand
Journal:  Surg Endosc       Date:  1996-12       Impact factor: 4.584

2.  Efficiency and Safety of One-Step Procedure Combined Laparoscopic Cholecystectomy and Eretrograde Cholangiopancreatography for Treatment of Cholecysto-Choledocholithiasis: A Randomized Controlled Trial.

Authors:  Zhiyi Liu; Luyao Zhang; Yanling Liu; Yang Gu; Tieliang Sun
Journal:  Am Surg       Date:  2017-11-01       Impact factor: 0.688

3.  Updated guideline on the management of common bile duct stones (CBDS).

Authors:  Earl Williams; Ian Beckingham; Ghassan El Sayed; Kurinchi Gurusamy; Richard Sturgess; George Webster; Tudor Young
Journal:  Gut       Date:  2017-01-25       Impact factor: 23.059

4.  Comparison of Efficacy and Safety of 4 Combinations of Laparoscopic and Intraoperative Techniques for Management of Gallstone Disease With Biliary Duct Calculi: A Systematic Review and Network Meta-analysis.

Authors:  Claudio Ricci; Nico Pagano; Giovanni Taffurelli; Carlo Alberto Pacilio; Marina Migliori; Franco Bazzoli; Riccardo Casadei; Francesco Minni
Journal:  JAMA Surg       Date:  2018-07-18       Impact factor: 14.766

Review 5.  One-stage laproendoscopic procedure versus two-stage procedure in the management for gallstone disease and biliary duct calculi: a systemic review and meta-analysis.

Authors:  Pankaj Prasson; Xueli Bai; Qi Zhang; Tingbo Liang
Journal:  Surg Endosc       Date:  2015-12-30       Impact factor: 4.584

6.  Single-stage laparoscopic common bile duct exploration and cholecystectomy versus two-stage endoscopic stone extraction followed by laparoscopic cholecystectomy for patients with concomitant gallbladder stones and common bile duct stones: a randomized controlled trial.

Authors:  Virinder Kumar Bansal; Mahesh C Misra; Karthik Rajan; Ragini Kilambi; Subodh Kumar; Asuri Krishna; Atin Kumar; Chandrakant S Pandav; Rajeshwari Subramaniam; M K Arora; Pramod Kumar Garg
Journal:  Surg Endosc       Date:  2013-10-26       Impact factor: 4.584

7.  The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.

Authors:  Brian Hutton; Georgia Salanti; Deborah M Caldwell; Anna Chaimani; Christopher H Schmid; Chris Cameron; John P A Ioannidis; Sharon Straus; Kristian Thorlund; Jeroen P Jansen; Cynthia Mulrow; Ferrán Catalá-López; Peter C Gøtzsche; Kay Dickersin; Isabelle Boutron; Douglas G Altman; David Moher
Journal:  Ann Intern Med       Date:  2015-06-02       Impact factor: 25.391

8.  Estimating the mean and variance from the median, range, and the size of a sample.

Authors:  Stela Pudar Hozo; Benjamin Djulbegovic; Iztok Hozo
Journal:  BMC Med Res Methodol       Date:  2005-04-20       Impact factor: 4.615

9.  Endoscopic versus laparoscopic treatment for choledocholithiasis: a prospective randomized controlled trial.

Authors:  Javier Ernesto Barreras González; Rafael Torres Peña; Julián Ruiz Torres; Miguel Ángel Martínez Alfonso; Raúl Brizuela Quintanilla; Maricela Morera Pérez
Journal:  Endosc Int Open       Date:  2016-11

10.  A randomized controlled trial of emergency LCBDE + LC and ERCP + LC in the treatment of choledocholithiasis with acute cholangitis.

Authors:  Qi Zou; Yue Ding; Chun-Sheng Li; Xiao-Ping Yang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-07-30       Impact factor: 1.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.